JPMorgan Chase & Co. Sells 20,348 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

JPMorgan Chase & Co. trimmed its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 7.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 236,368 shares of the biotechnology company’s stock after selling 20,348 shares during the quarter. JPMorgan Chase & Co.’s holdings in Arcturus Therapeutics were worth $4,011,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of ARCT. Franklin Resources Inc. lifted its position in Arcturus Therapeutics by 54.6% during the third quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company’s stock worth $2,412,000 after purchasing an additional 36,714 shares during the period. Empire Life Investments Inc. raised its position in shares of Arcturus Therapeutics by 85.5% in the 4th quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company’s stock valued at $4,742,000 after buying an additional 128,771 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Arcturus Therapeutics by 139.7% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 82,057 shares of the biotechnology company’s stock worth $1,393,000 after acquiring an additional 47,824 shares during the period. Spire Wealth Management boosted its position in shares of Arcturus Therapeutics by 393.3% during the 4th quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company’s stock worth $229,000 after acquiring an additional 10,746 shares in the last quarter. Finally, SG Americas Securities LLC increased its stake in Arcturus Therapeutics by 45.0% in the fourth quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock valued at $203,000 after acquiring an additional 3,705 shares during the last quarter. 94.54% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on ARCT. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Arcturus Therapeutics in a report on Thursday, April 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research note on Friday, March 7th. BTIG Research set a $48.00 target price on Arcturus Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 10th. Canaccord Genuity Group reduced their price target on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating on the stock in a research note on Monday, March 10th. Finally, Wells Fargo & Company lowered their price objective on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $59.20.

Arcturus Therapeutics Trading Up 2.2 %

NASDAQ:ARCT opened at $10.53 on Monday. The stock’s 50-day moving average is $13.26 and its 200-day moving average is $16.38. The stock has a market cap of $285.57 million, a P/E ratio of -4.74 and a beta of 3.41. Arcturus Therapeutics Holdings Inc. has a 1-year low of $8.04 and a 1-year high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.78). The business had revenue of $22.77 million during the quarter, compared to analyst estimates of $44.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. As a group, equities analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.